Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px
Organisation › Details

Immunicum AB (publ; First North Premier: IMMU.ST)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST). *

 

Period Start 2002-01-01 splitoff
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 Intuvax®
Persons Person de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
  Person 2 Zeilemaker, Sijme (Immunicum 201703– Director Business Development before InteRNA Technologies + to-BBB Technologies)
     
Region Region Göteborg (Gothenburg)
  Country Sweden
  Street 2 Grafiska Vägen
  City 412 63 Göteborg
  Tel +46-31-415052
    Address record changed: 2016-05-07
     
Basic data Employees B: 11 to 50 (2017-03-31)
     
    * Document for �About Section�: Immunicum AB. (4/25/16). "Press Release: Immunicum Announces Fully Underwritten Rights Issue of about SEK 111 Million to Extend Phase II-Trial with New clinics in the US and to Initiate Clinical Trials in Melanoma in the US and in Sweden".
     
   
Record changed: 2018-02-06

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for Immunicum AB (publ; First North Premier: IMMU.ST)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px




» top